3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
7
Phase 1/2
6
Phase 2
5
Phase 3
3
Phase 2/3
2
Phase EARLY_PHASE1
1
Phase 4
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
FED
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other
1
Head & Neck
1
Conditions
Neoplasms
66
Breast Neoplasms
64
Prostatic Neoplasms
46
Carcinoma, Non-Small-Cell Lung
40
Neoplasm Metastasis
23
Colorectal Neoplasms
21
Multiple Myeloma
20
Pain
19
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
16
Anemia
16
Keratosis, Actinic
15
Lung Neoplasms
14
Cancer Pain
14
Lymphoma, Non-Hodgkin
12
Lymphoma, Follicular
11
Leukemia
11
Leukemia, Lymphocytic, Chronic, B-Cell
10
Carcinoma, Renal Cell
10
Carcinoma, Hepatocellular
9
Carcinoma
9
Neuroendocrine Tumors
8
Melanoma
8
Lymphoma
8
Ovarian Neoplasms
7
Leukemia, Myeloid, Acute
7
Uterine Cervical Neoplasms
6
Recurrence
6
Gastrointestinal Stromal Tumors
6
Stomatitis
5
Stomach Neoplasms
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 4
×
INDUSTRY
×
Neoplasms, Squamous Cell
×
Clear all
NCT01283906
2013-09-12
MuGard
Access Pharmaceuticals, Inc.
Phase 4
Completed
120 enrolled